 CStone Pharma out-licensed global rights ex-China for two immuno-oncology assets to US-based EQRx in a 1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Swedens BioInvent in a 95 million deal. 